Amplio Pharma AB is a novel and exciting product company developing improved versions of already great drugs.
Our first candidate drug product to have reached the clinical R&D stage is Methotrexate Forte. Formulated as an sc injectable, Methotrexate Forte has the ambition to become the market leading first choice drug product to treat autoimmune diseases like rheumatoid arthritis. This novel and proprietary drug product holds the promise to achieve low disease activity/disease remission in up to 70% of the patient population.
Amplio Pharma AB is founded, fully owned and managed by three female entrepreneurs, Charlott Brunmark, PhD (Chairwoman of the Board of Directors), Marguerite Mensonides, PhD (Vice chair of the BoD) and Karin von Wachenfeldt, PhD (CEO). Methotrexate Forte was invented by the same.